3,4-Dihydroquinazoline 1 as T-type calcium channel blocker was in vivo evaluated against A549 xenograft in BALB/c-nu Slc mice, which exhibited 54% tumor growth inhibition through oral administration of 8 mg/kg of body weight and was slightly less active than doxorubicin (68%). In addition, this compound was also profiled for its acute toxicity to ICR mice to afford oral LD50 value of 1,038 mg/kg of body weight.
CITATION STYLE
Park, H. A., Jung, S. Y., Lee, S. H., Kang, H. B., Min, M. S., Kim, J., … Lee, J. Y. (2010). Anti-cancer activity of T-type calcium channel blocker in vivo. Bulletin of the Korean Chemical Society, 31(11), 3353–3358. https://doi.org/10.5012/bkcs.2010.31.11.3353
Mendeley helps you to discover research relevant for your work.